Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight ≥ 40 kg;~* Recurrent abdominal pain or discomfort for three or more days per month for the last three months which meets Rome III criteria for non-constipating IBS;~* Patients on a stable diet for at least eight weeks;~* Patients ≥ 50 years of age with a negative screening colonoscopy in the last five years;~* Able and willing to comply with all protocol procedures for the planned duration of the study;~* Able and willing to understand, sign and date an informed consent document, and authorize access to protected health information,~* Females must be postmenopausal, surgically incapable of bearing children, or practicing a reliable method of birth control (intrauterine devices, spermicide and barrier) (Hormonal contraceptives are NOT regarded as adequate for the purpose of this trial.) Partner/spouse sterility may also qualify at the Investigator's discretion. Females of child-bearing potential must have a negative urine pregnancy test at baseline.~Exclusion Criteria:~* Constipating IBS;~* History of untreated lactose intolerance;~* History of colonic or major abdominal surgery (colectomy, for example);~* Active (untreated) Thyroid disease;~* Current diagnosis of major depression or psychosis;~* Known positive stool cultures for Clostridium difficile or other pathogens;~* Any condition necessitating the administration of analgesics (except paracetamol), probiotics, neuroleptics, antidepressants for IBS symptoms, daytime tranquilizers, prokinetics or spasmolytic medications;~* Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling;~* Other major physical or major psychiatric illness within the last six months that in the opinion of the investigator would affect the patient's ability to complete the trial;~* Uncontrolled systemic disease such as diabetes;~* Patients undergoing chemotherapy for the treatment of cancer;~* Known hypersensitivity or contraindication to any component of the test product (study drugs) or diagnostics used;~* Participation in another study within eight (8) weeks prior to the study;~* Unable to attend all visits required by the protocol;~* Female patients must be excluded if they are pregnant, breast feeding, or planning to become pregnant during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AST-120, 2 gram sachets
- 2 (Type: PLACEBO_COMPARATOR): Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets

Based on this trial design, predict the completion outcome and termination type (if applicable).